GSK is starting a Phase 3 trial of Benlysta (belimumab) in combination with Rituxan (rituximab) for treating…
Articles by Janet Stewart, MSc
ImmunoQure AG and Servier have entered into a strategic partnership to develop a new therapy that could benefit…
While lupus nephritis usually develops within five years of a systemic lupus erythematosus (SLE) diagnosis, a case study of three…
Benlysta (belimumab) used in combination with standard of care significantly improved disease activity and reduced prednisone use in patients in…
A new, simple blood test was found to be a good predictor of lupus nephritis (LN) relapses. LN is a…
Adherence among lupus patients to hydroxychloroquine (HCQ), the backbone of disease therapy, is suboptimal overall but particularly poor among those on…
Cellenkos announced a new collaboration with The University of Texas MD Anderson Cancer Center to develop cord blood regulatory…
The rate of cardiovascular events in lupus patients increased during the second half of a 15-year period, a long-term study…
The European Commission has approved the new, self-administered and injectable formulation of  Benlysta (belimumab), by GSK, as an…
Patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) showed no clinical benefit when treated with…